Male Genital Disorders |
Penile Disorders; Testicular Disorders |
Clinical Trial: Male Circumcision and HIV Rates in Kenya
This study is currently recruiting patients.
|
Purpose
The Luo tribe of Kisumu, Kenya, does not traditionally practice male circumcision (MC). This study will work with the Luo tribe to test the effectiveness of MC on reducing the risk of HIV infections in young men.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| HIV Infections | Procedure: male circumcision | Phase III |
MedlinePlus related topics: AIDS
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Placebo Control, Factorial Assignment, Safety/Efficacy Study
Official Title: Trial of Male Circumcision to Reduce HIV Incidence
Expected Total Enrollment: 3000
Study start: February 2002; Expected completion: February 2007
Since 1989, numerous epidemiological studies have reported a significant association between lack of male circumcision (MC) and risk for HIV infection through heterosexual intercourse. These results have led to calls for male circumcision to be considered as an additional HIV prevention strategy. However, there is a consensus among the international health community that a randomized controlled trial of MC is needed to control for possible confounding factors. Additionally, known risks associated with MC need further investigation. This study will assess the effectiveness of male circumcision in reducing HIV incidence and will evaluate complications of the MC procedure, changes in sexual behavior following circumcision, and the biological mechanisms by which the foreskin may increase HIV susceptibility. The study will be conducted in Kisumu, Kenya, where the Luo tribe is the main ethnic group and less than 10% of adult men are circumcised.
Uncircumcised men aged 18 to 24 years old will be offered voluntary HIV counseling and testing. HIV negative men will be asked to enroll in the study. All study participants will be interviewed to obtain socio-demographic information and assess behavioral risk factors. Participants will be examined for significant medical conditions. All men will be counseled in strategies to reduce their risk for HIV infection. Consenting men will be randomly assigned to either the treatment (circumcised) arm or the control (uncircumcised) arm of the study. After circumcision, men will be monitored for complications. They will be counseled to abstain from sex until healing is complete. Follow-up visits will occur every 6 months for 2 years. Uncircumcised men will be offered circumcision at the end of follow-up.
The primary study endpoints will be HIV incidence and surgical complications. Additional outcomes will be the incidence of other sexually transmitted diseases and behavioral risks. Additional laboratory studies of foreskin tissue will evaluate the number and density of specialized cells rich in HIV receptors in order to illuminate the biological mechanisms by which presence of foreskin may increase HIV susceptibility.
Eligibility
Ages Eligible for Study: 18 Years - 24 Years, Genders Eligible for Study: Male
Accepts Healthy Volunteers
Criteria
Inclusion Criteria
- HIV uninfected and willing to be tested
- Live in Kisumu District, Kenya
- Uncircumcised but willing to be circumcised
- At least one sexual partner in the 12 months prior to study entry
Location and Contact Information
Kenya
UNIM Clinic, Kisumu, Kenya; Recruiting
Kwango Agot, PhD, Sub-Investigator
Robert C. Bailey, PhD, MPH, Principal Investigator, University of Illinois
More Information
Record last reviewed: November 2004
Last Updated: November 2, 2004
Record first received: April 23, 2003
ClinicalTrials.gov Identifier: NCT00059371
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Ambiguous Genitalia (Mayo Foundation for Medical Education and Research)
- American Foundation for Urologic Disease

Not Signed In -

